Mixed signals: Biotech executives face conflicting signs on growth

Faced with conflicting signs from all sides of the biotech economy, executives are left sorting out how to plan for growth.

Previous Bank of America promotes Philly exec with oversight of Pittsburgh market president to bigger role
Next FDA gives Durham's BioCryst green light to resume trial enrollment

No Comment

Leave a reply

Your email address will not be published.